Nothing Special   »   [go: up one dir, main page]

EP3104881A4 - Selective reduction of proteins - Google Patents

Selective reduction of proteins Download PDF

Info

Publication number
EP3104881A4
EP3104881A4 EP15749202.6A EP15749202A EP3104881A4 EP 3104881 A4 EP3104881 A4 EP 3104881A4 EP 15749202 A EP15749202 A EP 15749202A EP 3104881 A4 EP3104881 A4 EP 3104881A4
Authority
EP
European Patent Office
Prior art keywords
proteins
selective reduction
selective
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15749202.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3104881A1 (en
Inventor
Damon L. Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Priority to EP22202155.2A priority Critical patent/EP4190809A1/en
Publication of EP3104881A1 publication Critical patent/EP3104881A1/en
Publication of EP3104881A4 publication Critical patent/EP3104881A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP15749202.6A 2014-02-11 2015-02-11 Selective reduction of proteins Withdrawn EP3104881A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22202155.2A EP4190809A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938378P 2014-02-11 2014-02-11
PCT/US2015/015369 WO2015123265A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22202155.2A Division EP4190809A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Publications (2)

Publication Number Publication Date
EP3104881A1 EP3104881A1 (en) 2016-12-21
EP3104881A4 true EP3104881A4 (en) 2017-09-27

Family

ID=53800577

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15749202.6A Withdrawn EP3104881A4 (en) 2014-02-11 2015-02-11 Selective reduction of proteins
EP22202155.2A Pending EP4190809A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22202155.2A Pending EP4190809A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Country Status (9)

Country Link
US (3) US10464997B2 (ja)
EP (2) EP3104881A4 (ja)
JP (4) JP6713931B2 (ja)
KR (2) KR20230088389A (ja)
CN (3) CN112979786A (ja)
CA (2) CA2938450C (ja)
HK (1) HK1231400A1 (ja)
MX (2) MX2016010295A (ja)
WO (1) WO2015123265A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
BR112016010169A2 (pt) 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
CN106104273A (zh) 2013-12-12 2016-11-09 施特姆森特克斯股份有限公司 新型抗dpep3抗体和使用方法
CA2938450C (en) 2014-02-11 2023-10-17 Seattle Genetics, Inc. Selective reduction of proteins
BR112016018891A2 (pt) 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
MX2017011281A (es) * 2015-03-09 2018-05-15 Heidelberg Pharma Gmbh Conjugados de amatoxina y anticuerpos.
AU2017218615B2 (en) 2016-02-12 2022-02-10 Byondis B.V. Selective reduction of cysteine-engineered antibodies
JP2019525727A (ja) * 2016-05-06 2019-09-12 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法
JP7073363B2 (ja) * 2016-11-07 2022-05-23 シージェン インコーポレイテッド 工学的に操作されたシステインキャップの分配
RU2759602C2 (ru) * 2017-02-08 2021-11-16 Пфайзер Инк. Процесс крупномасштабного производства кэпированных и некэпированных цистеинов антител и их применение для конъюгации терапевтических белков
CN107247144B (zh) * 2017-05-16 2019-12-24 上海科华生物工程股份有限公司 一种预处理丙肝抗原的方法和检测试剂盒
CN110831976A (zh) 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
LT3661562T (lt) * 2017-08-04 2024-10-25 Amgen Inc. Cys-mab konjugavimo būdas
CN107746424A (zh) * 2017-10-30 2018-03-02 上海药明生物技术有限公司 一种IgG4抗体的生物偶联方法
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
EP4488290A1 (en) * 2022-03-04 2025-01-08 ABTIS Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014339A1 (en) * 1994-11-05 1996-05-17 The Wellcome Foundation Limited Antibodies
WO2007003898A1 (en) * 2005-07-06 2007-01-11 Ucb Pharma S.A. Process for attaching effector molecules to proteins
WO2009092011A1 (en) * 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
WO2011061492A2 (en) * 2009-11-17 2011-05-26 Ucb Pharma S.A. Multivalent antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US20030105017A1 (en) 2001-07-10 2003-06-05 Gregory Conn Purification of human Troponin I
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
JP5335422B2 (ja) * 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN105198908B (zh) 2009-02-05 2019-12-24 伊缪诺金公司 新型苯并二氮杂*衍生物
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
CN103687623B (zh) 2011-02-15 2017-06-09 伊缪诺金公司 细胞毒性苯并二氮杂*衍生物
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CA2938450C (en) 2014-02-11 2023-10-17 Seattle Genetics, Inc. Selective reduction of proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014339A1 (en) * 1994-11-05 1996-05-17 The Wellcome Foundation Limited Antibodies
WO2007003898A1 (en) * 2005-07-06 2007-01-11 Ucb Pharma S.A. Process for attaching effector molecules to proteins
WO2009092011A1 (en) * 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
WO2011061492A2 (en) * 2009-11-17 2011-05-26 Ucb Pharma S.A. Multivalent antibodies

Also Published As

Publication number Publication date
CN111187348A (zh) 2020-05-22
WO2015123265A1 (en) 2015-08-20
EP3104881A1 (en) 2016-12-21
MX2020002791A (es) 2020-07-22
EP4190809A1 (en) 2023-06-07
JP6713931B2 (ja) 2020-06-24
CN106456725A (zh) 2017-02-22
US20200115438A1 (en) 2020-04-16
US20160347824A1 (en) 2016-12-01
KR102532137B1 (ko) 2023-05-12
US10464997B2 (en) 2019-11-05
HK1231400A1 (zh) 2017-12-22
CN106456725B (zh) 2021-03-12
MX2016010295A (es) 2016-10-17
JP2017506262A (ja) 2017-03-02
KR20230088389A (ko) 2023-06-19
US11667696B2 (en) 2023-06-06
CN106456725B9 (zh) 2022-08-09
JP2022153663A (ja) 2022-10-12
JP2025011264A (ja) 2025-01-23
KR20160136289A (ko) 2016-11-29
CA2938450A1 (en) 2015-08-20
US20230391848A1 (en) 2023-12-07
CA3211226A1 (en) 2015-08-20
JP2020143145A (ja) 2020-09-10
CA2938450C (en) 2023-10-17
CN112979786A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
HK1231400A1 (zh) 蛋白質的選擇性還原
EP3140722A4 (en) Characterizing states of subject
EP3212231A4 (en) Anti-tim-3 antibodies
EP3212229A4 (en) Anti-tim-3 antibodies
EP3134427A4 (en) Asx-specific protein ligase
EP3236772A4 (en) Methods of purifying recombinant proteins
EP3182985A4 (en) Fibroin-derived protein composition
EP3142680A4 (en) Lpa-associated protein and rna expression
IL252696B (en) protein production
EP3164410B8 (en) Protein recovery
PL3702450T3 (pl) Białko
EP3177650A4 (en) Anti-ceramide antibodies
GB201415344D0 (en) Protein
EP3384921A4 (en) NEW USE OF THIOPEPTIN
EP3209630A4 (en) Selective partial hydrogenation of beta-farnesene
EP3193878A4 (en) Compounds and methods
PL3099793T3 (pl) Białko
EP3204427A4 (en) Chimeric proteins
EP3149024A4 (en) Derivatives of dolaproine-dolaisoleuine peptides
EP3209697A4 (en) Fn14-binding proteins and uses thereof
AU2014902730A0 (en) Methods of inhibiting transmembrane proteins
AU2014902814A0 (en) Constrained proteins and uses therefor
AU2014904028A0 (en) Chimeric proteins
GB201414371D0 (en) Protein modification
AU2014903907A0 (en) Anti-CCR6 antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20170828

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101AFI20170822BHEP

Ipc: A61K 47/68 20170101ALI20170822BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231400

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEAGEN INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20221021

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231400

Country of ref document: HK